198 related articles for article (PubMed ID: 28258399)
1. Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies.
Nord E
Eur J Health Econ; 2018 Mar; 19(2):267-275. PubMed ID: 28258399
[TBL] [Abstract][Full Text] [Related]
2. Concerns for severity in priority setting in health care: a review of trade-off data in preference studies and implications for societal willingness to pay for a QALY.
Nord E; Johansen R
Health Policy; 2014 Jun; 116(2-3):281-8. PubMed ID: 24690334
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
[TBL] [Abstract][Full Text] [Related]
4. Severity-Adjusted Probability of Being Cost Effective.
Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
Nimdet K; Ngorsuraches S
BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis from a societal perspective.
Johannesson M; O'Conor RM
Health Policy; 1997 Mar; 39(3):241-53. PubMed ID: 10165464
[TBL] [Abstract][Full Text] [Related]
7. Resource allocation in decision support frameworks.
Phelps C; Madhavan G
Cost Eff Resour Alloc; 2018; 16(Suppl 1):48. PubMed ID: 30455607
[TBL] [Abstract][Full Text] [Related]
8. QALYs: are they helpful to decision makers?
McGregor M; Caro JJ
Pharmacoeconomics; 2006; 24(10):947-52. PubMed ID: 17002477
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
10. A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.
Franic DM; Bothe AK; Bramlett RE
J Fluency Disord; 2012 Dec; 37(4):300-13. PubMed ID: 23218213
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
12. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
[TBL] [Abstract][Full Text] [Related]
13. QALYs and ambulatory status: societal preferences for healthcare decision making.
Freath LL; Curry AS; Cork DMW; Audhya IF; Gooch KL
J Med Econ; 2022; 25(1):888-893. PubMed ID: 35713217
[TBL] [Abstract][Full Text] [Related]
14. Effect of obesity on cost per quality-adjusted life years gained following anterior cervical discectomy and fusion in elective degenerative pathology.
Chotai S; Sielatycki JA; Parker SL; Sivaganesan A; Kay HL; Stonko DP; Wick JB; McGirt MJ; Devin CJ
Spine J; 2016 Nov; 16(11):1342-1350. PubMed ID: 27394664
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective.
Ademi Z; Gloy V; Glinz D; Raatz H; Van Stiphout J; Bucher HC; Schwenkglenks M
Swiss Med Wkly; 2016; 146():w14382. PubMed ID: 27922167
[TBL] [Abstract][Full Text] [Related]
16. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.
Stolk EA; van Donselaar G; Brouwer WB; Busschbach JJ
Pharmacoeconomics; 2004; 22(17):1097-107. PubMed ID: 15612829
[TBL] [Abstract][Full Text] [Related]
17. Willingness to pay for a QALY: theoretical and methodological issues.
Gyrd-Hansen D
Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
[TBL] [Abstract][Full Text] [Related]
18. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: An Economic Analysis.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(6):1-51. PubMed ID: 27110317
[TBL] [Abstract][Full Text] [Related]
19. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
